Remove Development Remove Gene Expression Remove In-Vitro Remove Research
article thumbnail

Start-up to study peptides that modulate gene expression

Drug Discovery World

HBCI was established as a subsidiary of HBC earlier this year, with a focus on the discovery and development of peptides that normalise tumour micro-environments, resulting in the improved performance of immunotherapies and chemotherapies. Other potential cancer indications with ongoing in vitro work include breast and ovarian cancer.

article thumbnail

Quantitative approach on understanding how epigenetic switches control gene expression

Scienmag

Credit: Nucleic Acids Research Scientists at Tokyo Institute of Technology decipher how to quantitatively assess the effects of specific epigenetic changes on the rate of transcription by developing a mathematical model. For this, they successfully generated reconstituted chromatin bearing histone modifications in vitro.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.

RNA 40
article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

To address these problems, it’s vital to develop delivery systems that enable oligonucleotides to reach their targets: cell-penetrating peptides (CPPs) present a potential solution to this issue. Bachem has spent time studying and researching this reaction, along with the side-reactions that happen during the coupling stage.

article thumbnail

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Delveinsight

The first sign of a child suffering from Angelman syndrome is a delay in development, such as the inability to sit without support or making incoherent babbling sounds. Angelman syndrome is a result of the missing or dysfunctional gene known as UBE3A. GeneTx and Ultragenyx are co-developing the therapy.

article thumbnail

Fibrosis research: Advances and challenges 

Drug Discovery World

Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. This has hindered development of drugs so that, from a therapeutic intervention point of view, fibrosis research is still in its infancy.

article thumbnail

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52